Compare Monster Beverage Corp (MNST) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Nuvalent Inc — how do they compare? Monster Beverage Corp trades at $94.47 (market cap $93.35B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Monster Beverage Corp is far larger — about 9.5× Nuvalent Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals.
| MNST | NUVL | |
|---|---|---|
Market Cap | $93.35B | $9.81B |
Sector | Consumer Staples | Technology |
52-Week High | $99.94 | $123.96 |
52-Week Low | $58.75 | $72.16 |
Enterprise Value | $91.65B | $8.52B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
